NASDAQ:HOOK
Hookipa Pharma Inc. Stock News
$0.768
-0.0320 (-4.00%)
At Close: May 10, 2024
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA to Participate in the JMP Securities Life Sciences Conference
11:00am, Thursday, 09'th Jun 2022 GlobeNewswire Inc.
NEW YORK and VIENNA, Austria, June 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary are
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
01:00pm, Sunday, 05'th Jun 2022 GlobeNewswire Inc.
NEW YORK and VIENNA, Austria, June 05, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary are
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
11:00am, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
NEW YORK and VIENNA, Austria, June 03, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary are
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
09:15pm, Thursday, 26'th May 2022 GlobeNewswire Inc.
NEW YORK and VIENNA, Austria, May 26, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary aren
NEW YORK and VIENNA, Austria, May 26, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
12:15pm, Monday, 16'th May 2022 Zacks Investment Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -233.33% and 93.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
09:47am, Monday, 16'th May 2022
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -233.33% and 93.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates
09:25pm, Thursday, 12'th May 2022 Zacks Investment Research
CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
01:15pm, Tuesday, 10'th May 2022 Zacks Investment Research
Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
07:00am, Monday, 09'th May 2022
NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir
Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue Estimates
10:05pm, Thursday, 05'th May 2022 Zacks Investment Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Lags Revenue Estimates
01:15pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
03:01pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary ar
Hookipa Shares Jump On New Preclinical Data On Cancer Immunotherapies
11:52am, Wednesday, 13'th Apr 2022
HOOKIPA Pharma Inc (NASDAQ: HOOK) has announced preclinical data demonstrating potent T cell responses, combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various
